Non-small cell lung cancer (NSCLC)
The more common group. It includes adenocarcinoma, squamous cell carcinoma and other less common subtypes. The subtype and molecular findings help guide treatment.
LUNG CANCER
Lung cancer is not one single disease. The type, stage and biological features help determine the most appropriate care.
A guide for patients and families — from recognising symptoms and understanding tests to discussing treatment, support and follow-up.
Lung cancer starts when cells in the lung grow out of control. It can begin in the airways or lung tissue and may spread to nearby lymph nodes or distant organs. Cancer that starts elsewhere and spreads to the lung is named after its original site and is treated differently.
A lung nodule is a small spot seen on a scan. Many nodules are benign, including scars or changes from infection. Size, appearance, growth and individual risk determine whether follow-up scans or a biopsy are needed.
The more common group. It includes adenocarcinoma, squamous cell carcinoma and other less common subtypes. The subtype and molecular findings help guide treatment.
Usually grows and spreads more quickly. It often responds initially to chemotherapy and radiotherapy, but recurrence is common. Its treatment pathway differs from NSCLC.
Other lung tumours, such as carcinoid tumours, have their own biology and treatment. The exact pathology diagnosis matters.
Tobacco smoking is the leading preventable risk factor. Cigarettes, bidis and other smoked tobacco are harmful; no smoked tobacco product is safe. Risk generally rises with the amount smoked and the number of years of exposure.
Risk factors increase probability; they do not establish a diagnosis. Reduce avoidable exposures and use appropriate workplace protection. See cancer prevention.
Yes. Lung cancer can develop in never-smokers, including younger adults. Environmental exposures and changes acquired within lung cells may contribute; often no single cause can be identified.
Some treatable molecular alterations are more frequent in never-smokers, but smoking history cannot tell us which alteration a tumour has. Relevant testing should be based on the cancer and clinical setting. Nobody deserves blame for a cancer diagnosis.
These symptoms often have causes other than cancer. Arrange medical assessment when they are persistent, unexplained or worsening. Do not assume a cough is only due to smoking, allergy or infection. Tuberculosis and lung cancer can resemble one another and need appropriate investigation.
Coughing blood warrants prompt assessment. Severe symptoms require urgent care; do not wait several weeks. Read more about warning signs.
Yes. A small tumour may not cause pain, cough or breathing difficulty. Some cancers are discovered incidentally or through screening. Feeling well, having a normal blood count or having no smoking history does not exclude lung cancer.
A normal chest X-ray cannot reliably rule out every lung cancer. Persistent symptoms need clinical reassessment even after an initially reassuring test.
Screening is testing people without symptoms. Annual low-dose computed tomography (LDCT) can reduce lung-cancer deaths in appropriately selected high-risk people. It uses less radiation than a standard diagnostic chest CT. Chest X-rays and routine blood tests are not effective substitutes for LDCT screening.
As one example, the United States USPSTF recommendation covers adults aged 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. One pack-year means about 20 cigarettes daily for one year; one pack daily for 20 years equals 20 pack-years. Screening stops when eligibility ends or health substantially limits the ability to benefit from curative treatment.
Guidelines differ. The American Cancer Society guideline does not use a 15-year quit-time cut-off. These are US criteria, not a universal Indian screening policy. Discuss locally appropriate eligibility with a clinician; bidi and other tobacco exposure should be assessed individually.
Possible harms include false alarms, incidental findings, extra scans or procedures, radiation exposure and overdiagnosis of cancers that would not have caused harm. Screening requires shared decision-making and reliable follow-up. Routine screening for all never-smokers is not established.
Symptoms need diagnostic assessment, even if you are too young or otherwise ineligible for screening.
Visit our screening guide.
Assessment combines symptoms, examination, imaging and usually a tissue or cell sample. A chest CT describes the abnormality and helps plan sampling. PET-CT may help assess spread when it will change treatment; infection and inflammation can also light up on PET, so uptake alone does not prove cancer.
Bronchoscopy examines the airways. Endobronchial ultrasound (EBUS) can guide sampling of lymph nodes within the chest. A CT-guided needle biopsy may suit a more peripheral lesion. Sometimes pleural fluid, an accessible lymph node or another site provides the safest useful sample.
The team selects a procedure that can establish the diagnosis, help staging and preserve enough material for relevant tests. Learn more in Understanding Your Cancer Diagnosis.
A scan shows an abnormality; a pathologist examines sampled cells to identify what it is. Tissue or suitable cell samples usually confirm the cancer type and enable biomarker testing. Occasionally a multidisciplinary team recommends a different approach when biopsy is unsafe or impractical.
An appropriately performed biopsy does not ordinarily make cancer spread through the body. The benefits and procedure-specific risks should be discussed. Lung biopsy can cause bleeding or an air leak around the lung (pneumothorax), which sometimes requires treatment. Fear of spreading cancer should not prevent a needed diagnostic procedure.
The report identifies the type of cancer and may use immunohistochemistry (IHC), special stains that detect proteins, to clarify its origin and subtype. A biopsy report may be followed by separate molecular and PD-L1 reports.
A small or damaged sample may require repeat sampling. A preliminary diagnosis does not always contain everything needed to choose treatment.
Stage describes the extent of cancer. NSCLC is usually staged using TNM: the primary tumour (T), regional lymph nodes (N) and distant metastases (M). Stages I–II are generally more localised; stage III involves more extensive local or regional disease; stage IV indicates metastatic disease, which can include malignant fluid around the lung.
SCLC also uses TNM, but is often described as limited-stage (disease that can be encompassed in a suitable chest radiation field) or extensive-stage (spread beyond that extent).
CT, PET-CT, brain MRI and lymph-node sampling are used selectively. PET-CT does not reliably replace brain MRI. Clinical stage before treatment can differ from pathological stage after surgery. Stage is not the same as tumour grade.
Molecular tests look for changes that help cancer cells grow. Broad next-generation sequencing (NGS) can examine many genes together and is especially important in advanced non-squamous NSCLC. Testing is also relevant in selected squamous cancers and earlier-stage settings where results can affect treatment.
A suitable panel should detect the relevant types of alteration, including mutations and fusions; RNA-based testing may improve detection of some fusions. A negative result is only as informative as the sample quality and the test’s coverage.
When clinically feasible, key molecular results should be available before choosing first systemic treatment for advanced NSCLC. Urgent symptoms may require treatment while the team coordinates testing. Ask what is being tested, how long it takes and whether results could change the plan.
The exact alteration matters, not just the gene name. These findings may identify targeted treatment options in appropriate NSCLC settings; eligibility depends on disease stage, previous treatment, local approval and availability.
An uncertain variant is not automatically a treatment target. Having an actionable alteration increases treatment possibilities but does not guarantee response or cure.
PD-L1 is a protein usually assessed by IHC on tumour material. In NSCLC it is commonly reported as a tumour proportion score (TPS), the percentage of viable tumour cells staining for PD-L1. It helps inform some immunotherapy choices.
High PD-L1 does not guarantee benefit, and a low or negative result does not rule out benefit from every immunotherapy-containing regimen. Molecular drivers, cancer type, stage, symptoms and general health must also be considered. PD-L1 testing and NGS answer different questions; neither replaces the other.
For cancers with certain actionable drivers, such as EGFR or ALK, an appropriate targeted approach is generally preferred in advanced disease even when PD-L1 is high. SCLC immunotherapy decisions do not usually require selection by PD-L1.
A blood-based molecular test can look for tumour DNA circulating in blood (ctDNA). It can complement tissue testing when tissue is limited, biopsy is difficult or speed matters, and can help investigate resistance after progression.
A negative blood test does not exclude a tumour alteration. Some cancers release little DNA into the bloodstream. Tissue testing may still be needed. Liquid biopsy generally does not replace tissue for the initial histological diagnosis or for identifying a change in cancer type.
Blood-based molecular testing for treatment selection is different from a routine blood count and is not a substitute for established LDCT screening.
Usually not. Many alterations detected in lung cancer are acquired within the tumour and are not passed to children. Tumour testing and inherited (germline) genetic testing are different.
Occasionally the findings or family history suggest a possible inherited predisposition. That requires separate assessment, counselling and, when appropriate, confirmation with a germline test. A tumour report alone should not be used to label relatives as at risk.
Treatment depends on the exact type and stage, molecular results, PD-L1 where relevant, lung and heart function, other illnesses, previous treatment and the person’s priorities. Age alone should not decide the plan.
A multidisciplinary team may include medical oncology, respiratory medicine, thoracic surgery, radiation oncology, radiology, pathology and supportive-care specialists. Ask whether the goal is cure, reducing recurrence risk, long-term control or symptom relief. Clinical trials may be appropriate at different stages.
Surgery is an important option for selected localised NSCLC when the tumour can be removed and the person can tolerate the operation. The operation may remove a lung segment, a lobe or, less often, an entire lung, together with assessment of lymph nodes.
Breathing tests and fitness assessment help estimate risk. Minimally invasive techniques may be suitable. The need for treatment before or after surgery depends on stage, lymph nodes, margins and biomarkers. Surgery is not the usual treatment for widespread disease and is used only in carefully selected very early SCLC.
Radiotherapy directs radiation at a defined area. Stereotactic body radiotherapy (SBRT/SABR) can offer curative treatment for selected early NSCLC, especially when surgery is unsuitable. Locally advanced disease may require a longer course combined with chemotherapy.
Radiotherapy also helps treat brain or bone metastases and symptoms such as pain or bleeding. Side effects depend on the area treated and can include fatigue, swallowing discomfort and lung inflammation. New breathlessness after chest radiotherapy needs assessment.
Chemotherapy treats cancer cells throughout the body. It remains important in both NSCLC and SCLC, including before or after surgery, alongside chest radiotherapy or as part of treatment for metastatic disease.
Drug selection depends on the subtype, organ function and treatment goal. It may be combined with immunotherapy. Possible effects include low blood counts, nausea, fatigue, neuropathy or hair loss, but these vary by regimen. Preventive medicines and dose adjustments can help. Fever during chemotherapy requires prompt contact with the oncology team.
Targeted medicines act on specific cancer-driving alterations. Many are tablets, while some are infusions or antibody-based treatments. Some can also control disease in the brain. The right drug depends on the precise alteration and treatment setting.
Targeted therapy is not automatically suitable for everyone or free of side effects. Rash, diarrhoea, liver changes and, with particular drugs, heart effects or lung inflammation need monitoring. Medicines and supplements can interact. Do not stop, change or combine treatments without the treating team.
Immune checkpoint inhibitors help the immune system attack cancer. They may be used alone or in combinations, depending on stage, subtype, biomarkers and fitness. They can be used in selected earlier-stage settings as well as advanced disease.
They do not benefit everyone. Immune activation can inflame healthy organs, including the lungs, bowel, liver, thyroid and other endocrine glands; rare complications can be severe. New breathlessness, persistent diarrhoea, jaundice or marked weakness should be reported promptly, even after treatment has stopped. Autoimmune disease and organ transplantation require particular assessment.
Treatment often aims for cure. Surgery is a common approach when feasible; SBRT is an important alternative for selected people who cannot undergo surgery. Treatment around surgery may include chemotherapy, immunotherapy or targeted therapy according to the stage and tumour findings.
Not every small tumour requires every treatment. The operation’s pathology findings and relevant biomarkers help determine whether additional therapy is likely to reduce recurrence risk. Follow-up remains important after treatment.
Stage III is a varied group. Some tumours can be managed with surgery as part of a planned combination approach; others are unresectable and are often treated with chemotherapy and radiotherapy, given together when suitable.
Additional treatment after chemoradiotherapy depends on response, recovery and molecular findings. Immunotherapy is appropriate for many eligible patients; selected EGFR-mutated cancers may instead have an EGFR-targeted consolidation option. These approaches are not automatically interchangeable. Multidisciplinary assessment is essential.
Treatment usually aims to control cancer, relieve symptoms and extend life while preserving quality of life. Molecular findings may guide targeted therapy. Without an appropriate target, chemotherapy, immunotherapy or a combination may be recommended according to PD-L1, histology and clinical factors.
Some people achieve prolonged control. Treatment can change over time as response, tolerability and cancer biology change. Carefully selected patients with only a few metastatic or progressing sites may benefit from local treatment in addition to systemic therapy. This is an individual team decision, not a universal route to cure.
For suitable patients, chemotherapy and chest radiotherapy are usually combined with curative intent. Selected patients without progression after chemoradiotherapy may receive consolidation immunotherapy. Surgery is reserved for uncommon, very early node-negative cases after careful staging and usually requires additional chemotherapy.
A platinum-based chemotherapy combination with immunotherapy is commonly used for eligible patients, followed by ongoing treatment as appropriate. Radiotherapy can help selected chest disease or symptoms. At relapse, further systemic treatment and clinical trials may be considered according to the interval, fitness and available options.
Brain surveillance and possible preventive brain radiotherapy (prophylactic cranial irradiation) need an individual discussion of benefits, memory-related risks and MRI follow-up. They are not the same choice for every patient.
Brain metastases remain lung cancer, rather than a new primary brain cancer. MRI helps define their extent. Management may involve a brain-active systemic medicine, stereotactic radiotherapy, surgery or whole-brain radiotherapy, depending on the number, size, symptoms and overall situation.
Medicines may be used for swelling or seizures when indicated. New seizures, one-sided weakness, confusion or severe worsening headache require urgent assessment. Treatment timing is especially important when symptoms or pressure effects are present.
Bone metastases can cause pain, fractures or, in the spine, pressure on nerves. Treatment may include systemic therapy, local radiotherapy, pain relief and orthopaedic stabilisation when needed.
Bone-strengthening medicines may reduce some complications in selected patients. Dental assessment, calcium levels and kidney function may affect their safe use. New back pain with weakness, numbness or bladder or bowel changes is an emergency because of possible spinal cord compression.
The team considers symptoms, examination, scheduled imaging and relevant blood tests together. Scans may show a response, stable disease or progression. Stable disease can be a worthwhile result when the aim is control.
A scan does not need to become completely normal for treatment to help; residual abnormalities may include scar tissue. Conversely, feeling better alone cannot prove all cancer is controlled. PET-CT is not necessary for every assessment. Scan timing and interpretation depend on the treatment and clinical question.
Immune-related scan changes occasionally complicate interpretation. Do not assume worsening symptoms or a larger lesion are harmless “pseudoprogression”; the oncology team must assess them.
Yes. Resistant cancer-cell populations can grow despite a treatment that previously worked. New molecular changes or, less commonly, transformation into a different histological type can alter the next treatment choice.
Repeat tissue biopsy or liquid biopsy may help after progression. A tissue sample is particularly useful when transformation is suspected. The team also considers adherence, interactions, the pattern of progression and whether a few sites or many sites are growing. Progression does not necessarily mean all treatment options are exhausted.
Supportive care addresses breathlessness, pain, cough, fatigue, appetite, nutrition, sleep and emotional distress. Treatable problems such as infection, anaemia, fluid around the lung or airway obstruction may need specific management.
Palliative care can begin alongside active cancer treatment. It helps with symptom control, communication, family support and decisions that reflect the person’s priorities. It is not limited to the last days of life and does not mean giving up.
Discuss activity within your ability, rehabilitation, financial concerns and caregiver needs. Tell the team about all supplements and alternative remedies; “natural” does not mean safe or effective against cancer.
Stopping smoking is valuable even after a diagnosis. It can improve healing and treatment tolerance and reduce the risk of other illnesses and further cancers. It is never a reason to withhold compassionate care.
Ask for a practical cessation plan. Counselling and suitable medicines, including nicotine replacement or other prescribed treatments, can help manage dependence. A lapse is a reason to adjust support, not abandon the attempt. Keep the home smoke-free and involve supportive family members if you wish.
Many early-stage lung cancers are potentially curable. Some locally advanced cancers are also treated with curative intent. Metastatic lung cancer is usually treated for control rather than cure, but some patients live for prolonged periods with effective treatment.
Outcomes depend on stage, cancer type, molecular findings, general health and response. A population survival statistic cannot predict one person’s future and may reflect older treatments. Five-year survival is a statistical measure, not a deadline or a guarantee of cure. Ask your oncologist for an explanation appropriate to your situation and how uncertainty affects that estimate.
YOUR APPOINTMENT CHECKLIST
See more myths and facts.
For severe symptoms, go to emergency care immediately. Do not wait for a routine appointment or an online reply. Contact your oncology team promptly for other new or worsening treatment-related symptoms.
This educational guide draws on the following evidence-based resources. Screening criteria are labelled by their originating organisation; recommendations, approvals and availability vary by country and evolve over time.
Sources checked: 4 October 2026. This guide explains general principles, not individual treatment eligibility or a prescription. Reference to these organisations does not imply endorsement or affiliation.
Dr Hakeem Ansar Hussain
Medical Oncologist
Last medically reviewed:
The information on Cancer Aware is provided for general education and awareness only. It is not a substitute for consultation, diagnosis or treatment by a qualified healthcare professional. If you have persistent, worsening or concerning symptoms, please seek medical advice.